Updated:
Neo Kuma Ventures
Neo Kuma Ventures is the largest Europe-focused venture fund exclusively backing psychedelic healthcare, from compounds to digital therapeutics.
Neo Kuma Ventures
Neo Kuma Ventures operates out of London as a venture investor focused entirely on early-stage psychedelic healthcare. Burtenshaw, a former Slaughter and May lawyer and biotech investor named among the most influential women in psychedelics by Business Insider, runs the firm alongside McLintock, an entrepreneur with family office and trade finance experience, and Argyle, whose career spans Blackrock and boutique investment roles across credit and equity markets. A venture partner bench of chemical biology and neuropharmacology PhDs — Dr. Peter Crane and Dr. Willem Hendrik Gispen — reinforces the firm's scientific diligence. The firm deploys across three investment categories: compounds, clinics and care delivery, and digital therapeutics. Confirmed portfolio positions include Atai Life Sciences, Beckley Psytech, Bright Minds Biosciences, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp and Neurocentrx. Neo Kuma describes its geographic mandate as global with a European tilt, reflecting both the regulatory momentum in jurisdictions such as the UK and the firm's own London base. Neo Kuma has not publicly disclosed total assets under management or deployment figures, and its professional headcount remains unstated beyond the named investment professionals and advisory board. The firm's advisory board includes General Partners from Outsized Ventures, an early-stage life sciences fund, as well as the co-founder of Andela. Its regulatory structure — an Appointed Representative of The Fund Incubator Limited, authorised by the FCA — positions it as a tightly managed early-stage vehicle rather than a diversified platform. The firm's defining architecture is its single-sector mandate: it does not maintain a generalist healthcare practice, nor does it dilute its focus across biotech broadly. That purity of thesis, combined with a built-in network of operators and researchers, makes Neo Kuma a concentrated vehicle for investors seeking exposure to psychedelic medicine before the regulatory pathways fully solidify.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
71-75 Shelton Street, Covent Garden, London WC2H 9JQ, United Kingdom
Principals
Clara Burtenshaw
Investor
Sean McLintock
Investor
Fergus Argyle
Investor
Dr. Peter Crane
Venture Partner
Dr. Willem Hendrik Gispen
Venture Partner
Isabel Fox
Advisory Board
Lomax Ward
Advisory Board
Christina Sass
Advisory Board
Sector focus
Frequently asked questions
What is Neo Kuma Ventures' investment mandate?
The firm invests exclusively in early-stage psychedelic healthcare companies across three categories: compounds, clinics and care delivery, and digital therapeutics. Its geographic focus is global with a European tilt, writing cheques between £150k and £1m from pre-seed to Series A (per firm website). Neo Kuma does not invest outside these categories or stages.
Who runs investment decisions at Neo Kuma Ventures?
Investment decisions are driven by Clara Burtenshaw, Sean McLintock and Fergus Argyle. Burtenshaw brings biotech and legal expertise — she was previously at Slaughter and May and ranked among the most influential women in psychedelics by Business Insider. McLintock has entrepreneurship and family office experience, while Argyle's investment background includes Blackrock. Venture partners Dr. Peter Crane and Dr. Willem Hendrik Gispen provide scientific diligence (per firm website).
How does Neo Kuma Ventures source proprietary deal flow?
Neo Kuma emphasizes its specialist network, with relationships in the psychedelic sector going back 15 years. The firm's advisory board includes Outsized Ventures General Partners Isabel Fox and Lomax Ward, as well as Andela co-founder Christina Sass. By operating as the largest Europe-dedicated venture fund in psychedelics, the firm positions itself as a hub that sees most early-stage deal flow in its niche before generalist investors (per firm website, Altss estimate).
Is Neo Kuma Ventures regulated?
Yes. Neo Kuma Ventures LLP is an Appointed Representative of The Fund Incubator Limited, which is authorised and regulated by the UK Financial Conduct Authority (FRN 208716) (per firm website). The firm is structured as an early-stage venture vehicle, not a multi-strategy asset manager.
Which portfolio companies has Neo Kuma Ventures disclosed?
The firm lists Atai Life Sciences, Beckley Psytech, Bright Minds Biosciences, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp and Neurocentrx among its portfolio (per firm website). These span the firm's three investment categories: compounds, clinics and care delivery, and digital therapeutics.
What investment stages does Neo Kuma Ventures target?
Neo Kuma writes its initial cheques from pre-seed to Series A, with an average ticket size of £150k to £1m (per firm website). The firm does not indicate participation in later-stage or growth rounds.
Does Neo Kuma Ventures operate as a single family office or a traditional venture fund?
Neo Kuma Ventures operates as a specialist venture capital fund, not a family office. Its status as an FCA Appointed Representative and its website positioning confirm it is a pooled investment vehicle raising external capital, not a single-family structure (per firm website). One of its principals, Sean McLintock, brings family office experience to the team, but the firm itself does not represent any single family's wealth.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: